Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Fineline Cube Dec 20, 2025
Company Deals

Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets

Fineline Cube May 21, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based...

Company Drug

Abbisko’s Pimitinib Granted Priority Review for TGCT Treatment in China

Fineline Cube May 21, 2025

Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its self-developed, highly selective small-molecule CSF-1R inhibitor,...

Company Drug

Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC

Fineline Cube May 21, 2025

China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for JMT106 Clinical Study in Solid Tumors

Fineline Cube May 21, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...

Company Drug

Zhaoke Ophthalmology’s Cyclosporine Eye Gel NDA Accepted by NMPA

Fineline Cube May 21, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that the New Drug Application (NDA) for its...

Company Medical Device

Johnson & Johnson MedTech Completes First PFA Surgeries with VARIPULSE Catheter in China

Fineline Cube May 21, 2025

US-based Johnson & Johnson MedTech announced the completion of the first batch of pulse electric...

Company Deals

Shanghai CureGene Completes Series B+ Financing to Advance CG-0255 Study

Fineline Cube May 21, 2025

China-based Shanghai CureGene Pharmaceutical Co., Ltd announced the completion of a Series B+ financing round,...

Company Deals

Regeneron Wins Auction for 23andMe’s Core Business Units

Fineline Cube May 21, 2025

US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid...

Company Drug

GSK’s Blenrep Receives Marketing Approval in Japan for Multiple Myeloma

Fineline Cube May 21, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...

Company Deals

Accurate Biotechnology Secures RMB 100M in Series B Funding for Organoid Technology

Fineline Cube May 21, 2025

Accurate Biotechnology, a Guangzhou-based biotech focused on organoid technology, reportedly raised RMB 100 million (USD...

Company Drug

Hainan Shuangcheng’s Generic Eptifibatide Gains TGA Marketing Approval in Australia

Fineline Cube May 21, 2025

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia’s Therapeutic...

Company Medical Device

Stryker’s OptaBlate BVN System Gains FDA 510(k) Clearance

Fineline Cube May 21, 2025

US-based Stryker (NYSE: SYK) announced this week that its OptaBlate Basivertebral Nerve Ablation (BVN) system...

Company Deals

Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis

Fineline Cube May 21, 2025

Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss–American biotech CRISPR Therapeutics (NASDAQ:...

Company Drug

Zai Lab’s ZL-1310 Receives FDA Fast Track Designation for SCLC

Fineline Cube May 21, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received Fast...

Company Deals

Porton and Hualong Biological Partner to Advance MATC Therapy

Fineline Cube May 21, 2025

Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd. has entered into a...

Company Drug

AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment

Fineline Cube May 20, 2025

France-based AB Science SA (EPA: AB) reported receiving patent protection in China for its lead...

Company Drug

4B Technologies Gains NMPA Approval for ALS Drug 4B02-01 Clinical Trials

Fineline Cube May 20, 2025

China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...

Company Deals

Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China

Fineline Cube May 20, 2025

US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...

Company Drug

Bayer’s Jivi Receives FDA Approval for Pediatric Hemophilia A Treatment

Fineline Cube May 20, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced this week that it has received an...

Company

Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike

Fineline Cube May 20, 2025

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2025 financial report for the...

Posts pagination

1 … 93 94 95 … 600

Recent updates

  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
  • Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.